$Quest Diagnostics (DGX.US)$PathAI + Invigorate + stable finance + qualified management team + decent PE. Will it dominate pathology and cancer diagnosis with AI in the future? Worth noting.
Quest Diagnostics' consistent ROCE and increased capital employed over the past five years suggest steady reinvestment at good returns. This trend, reflected in the stock's strong performance, is expected to continue.
The acquisition aligns with Quest's strategy to grow through accretive outreach laboratory acquisitions and expands its ability to serve providers and patients in Ohio and Pennsylvania.
The CEO of Quest Diagnostics, Jim Davis, believes Yuri Fesko's deep medical expertise and patient-care advocacy will greatly contribute to the company's strategic decisions. His appointment especially bolsters Quest's efforts to improve customer experiences via diagnostic innovations.
Quest Diagnostics shows favorable metrics with robust reinvestment strategies. Significant earnings growth and an anticipated rise in future ROE, despite a higher payout ratio, hint at other growth factors.
Bruski2023
ThirtyOne
:
It’s really disgusting when you think about it…you’re a career politician with a net worth of 20-30-100mil, some way more. You absolutely have all the insight and information needed for the fuckery
The Covid-19 pandemic isn’t over but the U.S. is already entering a new vaccine boom. But the delayed vaccine rollout continues to raise questions. CNN reports that the U.S. delayed a large-scale vaccine order out of fear of the shots expiring before being administered. Federal agencies are exploring new ways to provide vaccines more efficiently, but the supply shortage poses challenges. For the U.S. government,...
chris from queens
:
best comment for anyone reading this they will be pleasantly surprised if they are early to the party.... is a company that is very good in dealing with very infectious diseases and coming up with tests RAPID TEST! DYODD!!! $T2 Biosystems (TTOO.US)$
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Quest Diagnostics Stock Forum
Will it dominate pathology and cancer diagnosis with AI in the future? Worth noting.
He became a millionaire many times over on a modest federal salary from trading.
Take a look:
Thomas Carper bought 30k in $ProShares Short QQQ (PSQ.US)$ , an ultrashort $Invesco QQQ Trust (QQQ.US)$ index, on July 13 2023.
He hedged/shorted in the past with great results with $Advisorshares Trust Ranger Equity Bear Etf (HDGE.US)$ , ...
In reaction to earnings/guidance:
• $Super Micro Computer (SMCI.US)$ +18%, $Nokia Oyj (NOK.US)$ +7.7%, $Danaher (DHR.US)$ +6.3%, $RLI Corp (RLI.US)$ +5%, $CSX Corp (CSX.US)$ +4.3%, $Las Vegas Sands (LVS.US)$ +4.2%, $Alcoa (AA.US)$ +3.4%(also authorizes new $500 mln share repurchase program)
• $Steel Dynamics (STLD.US)$ +2.8%, $Herc Holdings (HRI.US)$ +2.6%, $Tesla (TSLA.US)$ +2.5%, $Philip Morris International (PM.US)$ +2.5%, $F.N.B. Corp (FNB.US)$ ...
• $Twitter (Delisted) (TWTR.US)$ +20.5% (Elon Musk discloses 9.2% passive stake)
• $Camtek (CAMT.US)$ +9.6%, $Perion Network (PERI.US)$ +6.6% (In reaction to earnings/guidance)
• $Niu Technologies (NIU.US)$ +5% (reports QI sales volume increased 9.4% yr/yr)
• $Iron Spark I Inc (ISAA.US)$ +3.4% (Hypebeast plans to list on NASDAQ through Merger with Iron Spark I)
• $Gatos Silver(Delisted) (GATO.US)$ +2.3% (Provides Bi-Weekly Status Report)
• $Verve Therapeutics (VERV.US)$ +1.8% (re...
• $DCP Midstream (DCP.US)$ : Evercore ISI Upgrades to Outperform from In Line - PT $42 (from $36)
• $Leslie's (LESL.US)$ : Goldman Sachs Upgrades to Buy from Neutral - PT $27 (from $26)
• $Logitech International (LOGI.US)$ : Goldman Sachs Upgrades to Buy from Neutral
• $NIO Inc (NIO.US)$ : UBS Upgrades to Buy from Neutral - PT $32 (from $46)
• $Ollie's Bargain Outlet (OLLI.US)$ : Wells Fargo Upgrades to Overweight from EqualWeight - PT $65 (from $45)
• $Oric Pharmaceuticals (ORIC.US)$ : Citigro...
No comment yet